<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045769</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.17.006</org_study_id>
    <nct_id>NCT04045769</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers</brief_title>
  <official_title>A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to&#xD;
      Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: This is a Phase 1, single-center, blinded (with respect to saroglitazar&#xD;
      magnesium and placebo administration), randomized, placebo- and active-controlled, 4-period&#xD;
      crossover study to investigate the effect of single therapeutic and supra-therapeutic (5×)&#xD;
      doses of saroglitazar magnesium on the corrected QT (QTc) interval in healthy subjects in&#xD;
      compliance with the current version of the International Council for Harmonisation E14&#xD;
      Guidelines.&#xD;
&#xD;
      After confirmation of eligibility, 52 subjects (at least 16 will be females) will be randomly&#xD;
      assigned to 1 of 4 treatment sequences using a William's design prior to study treatment&#xD;
      administration on Day 1 of Period 1. Randomized subjects will receive each of the 4 study&#xD;
      treatments across the 4 treatment periods separated by at least a 7-day washout period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Actual">December 2, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcF change-from-baseline</measure>
    <time_frame>Pre-dose (-1.0 hr) to 24 hours post dose</time_frame>
    <description>Linear-mixed model will be used to assess the effect of saroglitazar magnesium on cardiac repolarization on Day 1 to evaluate whether saroglitazar magnesium prolongs the QTcF when orally administered to healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saroglitazar and its metabolite saroglitazar sulfoxide plasma concentrations and placebo-corrected change-from-baseline QTcF</measure>
    <time_frame>Pre-dose (-1.0 hr) to 24 hours post dose</time_frame>
    <description>Quantification of the relationship between saroglitazar and its metabolite saroglitazar sulfoxide plasma concentrations and QTcF, using concentration-effect modeling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed and change-from-baseline HR, PR, RR, QRS, and QT and ECG morphological abnormalities</measure>
    <time_frame>Pre-dose (-1.0 hr) to 24 hours post dose</time_frame>
    <description>Evaluation of the effect of Saroglitazar magnesium on other ECG parameters (ventricular HR, PR, RR, QRS, QT) and ECG morphological abnormalities</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar magnesium 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar magnesium 4mg</intervention_name>
    <description>1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally</description>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <other_name>not any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>5 tablets of placebo to be administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>not any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400mg</intervention_name>
    <description>1 tablet of 400 mg Moxifloxacin to be administered orally</description>
    <arm_group_label>Active Control</arm_group_label>
    <other_name>not any</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar magnesium 20 mg</intervention_name>
    <description>5 tablets of 4 mg Saroglitazar magnesium to be administered orally</description>
    <arm_group_label>Study treatment 2</arm_group_label>
    <other_name>not any</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated written informed consent prior to any study-specific&#xD;
             procedures&#xD;
&#xD;
          2. Willing and able to comply with the study procedures, restrictions, and requirements.&#xD;
&#xD;
          3. At least (≥) 18 years of age and no more than (≤) 45 years of age a&#xD;
&#xD;
          4. Body mass index of 19.0 to 25.0 kg/m² (inclusive) with a body weight of 50 to 100 kg&#xD;
&#xD;
          5. non-smokers and must not drink alcohol (teetotal).&#xD;
&#xD;
          6. Subjects who, in the opinion of the Investigator, are healthy as determined by their&#xD;
             pre-study medical history, physical examination, and 12-lead ECG, and clinical&#xD;
             laboratory tests within the institutional normal range or judged as not clinically&#xD;
             significant by the Investigator, including the following parameters: hematology, serum&#xD;
             biochemistry, urinalysis, and serology.&#xD;
&#xD;
          7. Male subjects and female subjects of childbearing potential must practice highly&#xD;
             effective contraception during the study and be willing and able to continue&#xD;
             contraception for 90 days after their last administration of study treatment.&#xD;
&#xD;
          8. Systemic blood pressure with a systolic blood pressure of 100 to 140 mmHg and a&#xD;
             diastolic blood pressure of 60 to 90 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiovascular disease (eg, hypertension, arrhythmia, heart failure, long&#xD;
             QT syndrome, or other conditions/diseases causing prolongation of the QT/QTc&#xD;
             interval), in the opinion of the Investigator.&#xD;
&#xD;
          2. A prolongation of the QT interval corrected for HR using Fridericia's correction&#xD;
             (QTcF) interval (eg, repeated demonstration of a QTcF interval &gt;450 msec) before study&#xD;
             treatment administration.&#xD;
&#xD;
          3. Any clinically important abnormalities in the ECG at screening, check-in (Day -1), or&#xD;
             predose on Day 1. This includes subjects with any of the following:&#xD;
&#xD;
               1. PR interval &gt;210 msec;&#xD;
&#xD;
               2. QRS &gt;110 msec; or&#xD;
&#xD;
               3. HR &lt;45 beats per minute (bpm) or &gt;100 bpm.&#xD;
&#xD;
          4. A QRS and/or T-wave value that the Investigator judges to be unfavorable for&#xD;
             consistently accurate QT measurements (eg, indistinct QRS onset, low amplitude T-wave,&#xD;
             inverted or terminally-inverted T-wave, merged T/U-waves, indistinct T-wave offset, or&#xD;
             prominent U-wave that affects QT measurement).&#xD;
&#xD;
          5. History of additional risk factors for Torsades de Pointes or the presence of a family&#xD;
             history of short QT syndrome, long QT syndrome, sudden unexplained death at a young&#xD;
             age (≤40 years), drowning or sudden infant death syndrome in a first degree relative&#xD;
             (ie, biological parent, sibling, or child).&#xD;
&#xD;
          6. Use of medications in the 90 days before Day -1 of Period 1 that are known to prolong&#xD;
             the QT/QTc interval.&#xD;
&#xD;
          7. Has used prescription drugs and other substances (eg, dietary or herbal supplements&#xD;
             such as St John's Wort) known to be either significant enzyme inducers or enzyme&#xD;
             inhibitors within 4 weeks of Day 1 of Period 1, or use of grapefruit or similar&#xD;
             substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids,&#xD;
             pomelos, exotic citrus fruits or fruit juices) within 7 days of Day 1 of Period 1.&#xD;
&#xD;
          8. Has used prescription or over-the-counter medication, excluding routine vitamins but&#xD;
             including megadose vitamin therapy (intake of 20 to 600 times the recommended daily&#xD;
             dose), within 7 days of Day 1 of Period 1, unless agreed as not clinically relevant by&#xD;
             the Investigator and Sponsor.&#xD;
&#xD;
          9. Any history of malignant disease, including solid tumors, hematologic malignancies,&#xD;
             and including any carcinoma in situ.&#xD;
&#xD;
         10. Clinically significant allergies, as determined by the Investigator.&#xD;
&#xD;
         11. History of any clinically significant endocrine, hematologic, hepatic, immunologic,&#xD;
             metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other&#xD;
             major diseases, as determined by the Investigator.&#xD;
&#xD;
         12. History of unexplained syncopal or hypotensive episodes.&#xD;
&#xD;
         13. A positive cotinine test and positive breath test at screening or check-in (Day -1) of&#xD;
             Period 1.&#xD;
&#xD;
         14. Surgery within 12 months prior to check-in (Day -1) of Period 1 (other than minor&#xD;
             cosmetic surgery and minor dental surgery).&#xD;
&#xD;
         15. Subjects who have recent illness (eg, fever &gt;38°C) within 7 days of check-in (Day -1)&#xD;
             of Period 1.&#xD;
&#xD;
         16. Clinically significant abnormal hematology and serum biochemistry values, as&#xD;
             determined by the Investigator or any of the following values at screening or check-in&#xD;
             (Day -1) of Period 1:&#xD;
&#xD;
               1. Alanine aminotransferase, aspartate aminotransferase, or creatinine above their&#xD;
                  reference range.&#xD;
&#xD;
               2. Hemoglobin or platelets below their reference range.&#xD;
&#xD;
         17. Subjects with an absolute neutrophil count &lt;2.0 × 10³/μL at screening or check-in (Day&#xD;
             -1) of Period 1, any documented laboratory value &lt;1.5 × 10³/μL, or any documented&#xD;
             history of neutropenia.&#xD;
&#xD;
         18. Subjects with an estimated glomerular filtration rate (as defined by estimation of&#xD;
             creatinine clearance using the Modification of Diet in Renal Disease formula) of ≤80&#xD;
             mL/min/1.73m² at screening.&#xD;
&#xD;
         19. History of, or positive screening test for, hepatitis C infection (defined as positive&#xD;
             for hepatitis C virus antibody), hepatitis B infection (defined as positive for&#xD;
             hepatitis B surface antigen), or human immunodeficiency virus I or II.&#xD;
&#xD;
         20. Treatment with saroglitazar magnesium, or any other PPAR agonist within 90 days prior&#xD;
             to Day -1 of Period 1.&#xD;
&#xD;
         21. Treatment with another investigational drug or approved therapy for investigational&#xD;
             use within 90 days of Day -1 of Period 1 or 5 × the t1/2 (whichever is longer), or the&#xD;
             subjects is in follow-up for any other drug, biologic, or device study.&#xD;
&#xD;
         22. Current active infection or serious infection (eg, pneumonia, septicemia) within the&#xD;
             90 days prior to Day -1 of Period 1 as determined by the Investigator.&#xD;
&#xD;
         23. Female subjects who are pregnant, currently breastfeeding, or attempting to conceive.&#xD;
&#xD;
         24. Known hypersensitivity to either saroglitazar magnesium or other PPAR agonists, and or&#xD;
             the excipients in the saroglitazar magnesium tablet formulation.&#xD;
&#xD;
         25. Known hypersensitivity to moxifloxacin or other quinolones.&#xD;
&#xD;
         26. Blood donation in the past 90 days, or bone marrow or stem cell donor in the past 12&#xD;
             months prior to check-in (Day -1) of Period 1.&#xD;
&#xD;
         27. Any disorder that, in the Investigator's opinion, may interfere with study compliance,&#xD;
             such as significant mental, nervous disorder or other illness. In making this&#xD;
             assessment, the Investigator must refer to the study information provided including&#xD;
             the Investigator's Brochure, and the prescribing information for saroglitazar&#xD;
             magnesium.&#xD;
&#xD;
         28. Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol.&#xD;
&#xD;
         29. Inability to be venipunctured or tolerate venous puncture.&#xD;
&#xD;
         30. Any condition or abnormal baseline findings that in the Investigator's judgment might&#xD;
             increase the risk to the subject or decrease the chance of obtaining satisfactory data&#xD;
             needed to obtain the objective of the study.&#xD;
&#xD;
         31. Has acute gastrointestinal symptoms at the time of screening or check-in (Day -1) of&#xD;
             Period 1 (eg, nausea, vomiting, diarrhea, heartburn).&#xD;
&#xD;
         32. Other unspecified reasons that, in the opinion of the Investigator or the Sponsor,&#xD;
             make the subject unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Deven V Parmar, MD,FCP</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliantha Research Limited</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

